Chemical Component Summary

NameNirmatrelvir
Synonyms(1R,2S,5S)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide
Identifiers(1~{R},2~{S},5~{S})-~{N}-[(1~{S})-1-cyano-2-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]ethyl]-3-[(2~{S})-3,3-dimethyl-2-[2,2,2-tris(fluoranyl)ethanoylamino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
FormulaC23 H32 F3 N5 O4
Molecular Weight499.526
TypeNON-POLYMER
Isomeric SMILESCC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C
InChIInChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1
InChIKeyLIENCHBZNNMNKG-OJFNHCPVSA-N

Chemical Details

Formal Charge0
Atom Count67
Chiral Atom Count6
Bond Count69
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB16691 
NameNirmatrelvir
Groups
  • approved
  • investigational
DescriptionNirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CL<sup>PRO</sup>) inhibitor that is the subject of clinical trial NCT04756531.[L33354] 3CL<sup>PRO</sup> is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2.[A234224] Without the activity of the SARS-CoV-2 3CL<sup>PRO</sup>, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral replication.[A234224,A234229,A234234] In 2020, Pfizer was investigating another potential treatment for SARS-CoV-2, [PF-07304814].[L33359] Both drugs were inhibitors of SARS-CoV-2 3CL<sup>PRO</sup>, but nirmatrelvir has the advantage of being orally bioavailable.[L33359] Nirmatrelvir is advantageous in that it can be prescribed to patients before they require hospitalization, while [PF-07304814] requires intravenous administration in hospital.[L33359] In December 2021, the FDA granted an emergency use authorization to Paxlovid, a co-packaged product containing both nirmatrelvir and [ritonavir], for the treatment of certain patients with mild-to-moderate COVID-19.[L39544] It was fully approved by the FDA on May 25, 2023.[L46921] Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European Commission on January 27, 2022.[L40094]
SynonymsNirmatrelvir
Brand NamesPaxlovid
IndicationIn the US, Europe, and Canada, nirmatrelvir, in combination with [ritonavir], is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.[L46586, L39840] In Europe, this therapeutic indication is approved under conditional marketing authorization.[L40089]
Categories
  • Amides
  • Amino Acids
  • Amino Acids, Branched-Chain
  • Amino Acids, Cyclic
  • Amino Acids, Essential
ATC-CodeJ05AE30
CAS number2628280-40-8

Drug Targets

NameTarget SequencePharmacological ActionActions
Replicase polyprotein 1abMESLVPGFNEKTHVQLSLPVLQVRDVLVRGFGDSVEEVLSEARQHLKDGT...unknowninhibitor
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate,inhibitor
P-glycoprotein 1MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...unknownsubstrate,inhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem 155903259
ChEMBL CHEMBL4802135
ChEBI CHEBI:170007